Lenalidomide Fresenius Kabi (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, changing the complex’s substrate specificity. This leads to the degradation of transcription factors Ikaros and Aiolos, which suppresses angiogenesis, modulates cytokine release, and enhances T‑ and NK‑cell anti‑tumor activity, producing anti‑proliferative and pro‑apoptotic effects in malignant cells.

The dose of Lenalidomide is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and patient tolerance. Healthcare providers determine the appropriate strength, schedule, and any necessary dose adjustments, and patients should follow the prescriber’s written instructions exactly.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. Women of childbearing potential must use effective contraception. Breastfeeding is not recommended while taking Lenalidomide, as the drug may be excreted in milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

The primary alternative within the same class is thalidomide, while pomalidomide is a newer analogue. Compared with thalidomide, Lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, and provides stronger anti‑angiogenic and immunomodulatory effects. Pomalidomide may be used after Lenalidomide failure, but it can have a higher risk of hematologic toxicity.

Lenalidomide should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed. Do not store in a refrigerator or freezer unless the manufacturer’s labeling specifically indicates otherwise.

Lenalidomide is taken orally, usually as a tablet, with or without food according to the prescriber’s instructions. The medication should be swallowed whole with a full glass of water, and patients should follow any specific timing recommendations provided by their healthcare professional.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia leading to infection, hepatotoxicity indicated by elevated liver enzymes, and the potential development of secondary primary malignancies. Patients should be monitored regularly for signs of these conditions and report any concerning symptoms promptly.

Lenalidomide is contraindicated in pregnant women and in individuals who are unable to use effective contraception. It should also be avoided in patients with known hypersensitivity to Lenalidomide or any component of the formulation, and caution is advised in those with severe renal or hepatic impairment where the risk‑benefit ratio must be carefully evaluated.